Loading clinical trials...
Loading clinical trials...
An Open-label Phase 2 Multi-center Study of Enzalutamide and Abiraterone and Biomarkers of Androgen Response and Resistance During Rising PSA: BARRIER-P Trial
Conditions
Interventions
Abiraterone + prednisone
Enzalutamide
Locations
2
Canada
British Columbia Cancer Agency, Vancouver Cancer Centre
Vancouver, British Columbia, Canada
Princess Margaret Cancer Centre
Toronto, Ontario, Canada
Start Date
March 1, 2016
Primary Completion Date
September 1, 2019
Completion Date
September 1, 2019
Last Updated
January 13, 2020
NCT06844383
NCT05919264
NCT06615752
NCT06334120
NCT06190899
NCT07005154
Lead Sponsor
University Health Network, Toronto
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions